As of 2026-02-18, the Intrinsic Value of Hemogenyx Pharmaceuticals PLC (HEMO.L) is -901.24 GBP. This HEMO.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 892.00 GBP, the upside of Hemogenyx Pharmaceuticals PLC is -201.04%.
Based on its market price of 892.00 GBP and our intrinsic valuation, Hemogenyx Pharmaceuticals PLC (HEMO.L) is overvalued by 201.04%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -901.24 - -901.24 | -901.24 | -201.04% |
| DDM - Stable | (1,143.77) - (3,588.83) | (2,366.31) | -365.3% |
| DDM - Multi | (739.20) - (1,845.40) | (1,060.40) | -218.9% |
| Market Cap (mil) | 46.47 |
| Beta | -2.34 |
| Outstanding shares (mil) | 0.05 |
| Enterprise Value (mil) | 48.44 |
| Market risk premium | 5.98% |
| Cost of Equity | 10.47% |
| Cost of Debt | 5.00% |
| WACC | 10.13% |